NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
55513-0478-10 | 55513-0478 | Epoetin alfa | Epogen | 20000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Mar 3, 1997 | In Use | ||
00591-3592-60 | 00591-3592 | Dronabinol | Dronabinol | 5.0 mg/1 | Ancillary Therapy | Antiemetic | CB1/CB2 | Oral | Jun 7, 2005 | May 31, 2019 | No Longer Used |
68001-0285-36 | 68001-0285 | Leucovorin Calcium | Leucovorin | 10.0 mg/mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jul 1, 2016 | Feb 1, 2021 | No Longer Used |
44206-0458-24 | 44206-0458 | HUMAN IMMUNOGLOBULIN G | Hizentra | 0.2 g/mL | Ancillary Therapy | Immunostimulant | Human Immunoglobulin G | Subcutaneous | Jan 1, 2020 | In Use | |
00185-0155-01 | 00185-0155 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Apr 18, 2005 | Mar 31, 2012 | No Longer Used | |
00069-1309-04 | 00069-1309 | epoetin alfa-epbx | RETACRIT | 40000.0 [iU]/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Jun 18, 2018 | In Use | ||
61919-0087-30 | 61919-0087 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 29, 2019 | In Use | |
00781-3415-95 | 00781-3415 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.25 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Oct 1, 2024 | In Use | |
51655-0196-80 | 51655-0196 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 20, 2022 | In Use | |
23155-0547-41 | 23155-0547 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Jun 15, 2012 | In Use | |
64679-0662-02 | 64679-0662 | Granisetron Hydrochloride | Granisetron Hydrochloride | 0.1 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Mar 3, 2008 | In Use | |
63629-1585-03 | 63629-1585 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 30, 2007 | Feb 28, 2017 | No Longer Used |
45963-0538-30 | 45963-0538 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 27, 2007 | In Use | |
80425-0072-02 | 80425-0072 | Ondansetron 4mg, Ondansetron HCL | Ondansetron HCL | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
51079-0321-01 | 51079-0321 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jul 13, 2015 | Jun 30, 2019 | No Longer Used |
69639-0101-04 | 69639-0101 | Netupitant and Palonosetron | Akynzeo | 300.0 mg/1, 0.5 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 | Oral | Oct 13, 2014 | In Use | |
52125-0833-01 | 52125-0833 | Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant | GARDASIL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Feb 13, 2014 | Feb 11, 2015 | No Longer Used | |
58118-0240-08 | 58118-0240 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 2, 2007 | Jun 26, 2017 | No Longer Used |
67457-0430-10 | 67457-0430 | Pamidronate Disodium | Pamidronate Disodium | 3.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov 1, 2008 | In Use | ||
61314-0866-02 | 61314-0866 | Pegfilgrastim-bmez | ZIEXTENZO | 6.0 mg/.6mL | Ancillary Therapy | Immunostimulant | Colony-Stimulating Factor | Subcutaneous | Mar 3, 2025 | In Use | |
68788-8582-02 | 68788-8582 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 12, 2024 | In Use | |
50090-2342-00 | 50090-2342 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Apr 6, 2016 | Sep 30, 2018 | In Use |
00173-0447-02 | 00173-0447 | Ondansetron Hydrochloride | Zofran | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 11, 1993 | Aug 21, 2013 | No Longer Used |
72374-0102-10 | 72374-0102 | Filgrastim-txid | NYPOZI | 480.0 ug/480ug | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Dec 16, 2024 | In Use | |
55700-0627-20 | 55700-0627 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 18, 2018 | Jun 30, 2027 | In Use |
Found 11748 results — Export these results